DermatologyNews.net

Dermatology Xagena

XagenaNewsletter
Medical Meeting
Xagena Mappa
Gastrobase.it

Search results for "Nail psoriasis"

Phase II data, published in the New England Journal of Medicine ( NEJM ), have showen that Ixekizumab, an anti-IL-17 monoclonal antibody, met its primary endpoint in patients with moderate-to-severe p ...


New findings on Apremilast ( Otezla ), a selective inhibitor of phosphodiesterase 4 ( PDE4 ), from the ESTEEM 1 and 2 phase III studies in patients with moderate to severe plaque psoriasis were presen ...


A post hoc analysis has examined the effects of Adalimumab ( Humira ) in patients with scalp and/or nail psoriasis from BELIEVE, a randomized, controlled, multicentre phase 3 safety and efficacy trial ...


Results from additional efficacy and safety analyses of Apremilast ( Otezla ) from the ESTEEM phase III clinical trial program were presented at the 23rd European Academy of Dermatology and Venereolog ...


Psoriasis is a chronic inflammatory disease associated with increased risk of cardiovascular death. Several studies have shown a beneficial effect of anti-TNF-alpha therapy on the mechanisms associate ...


Findings of a phase 3 study of patients with moderate to severe psoriasis demonstrating that nearly half of adult patients treated with Adalimumab ( Humira ) has achieved at least a 75% improvement in ...


Nail psoriasis is associated with functional impairment, pain and reduced quality of life. The aim of a study was to demonstrate the superiority of Secukinumab ( Cosentyx ) versus placebo in cleari ...


Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A, is approved for the treatment of moderate-to-severe psoriasis. An overview has analyzed the efficacy o ...